Systemic treatment with recombinant NGF during the neonatal stage leads to a wide range of intestinal phenotypes, such as visceral hypersensitivity and disruption of the mucosal barrier, that can be observed in NMS-treated rats and human IBS patients19,20. The gene discussed is NGF; the disease is irritable bowel syndrome.